Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 123 for:    hypertension "vitamin d"

Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02245633
Recruitment Status : Unknown
Verified September 2014 by Sydney Ben Shitrit, Meir Medical Center.
Recruitment status was:  Recruiting
First Posted : September 19, 2014
Last Update Posted : September 19, 2014
Sponsor:
Information provided by (Responsible Party):
Sydney Ben Shitrit, Meir Medical Center

Brief Summary:

The aim of this research is to study how vitamin D affects various aspects of the disease process, such as inflammation, coagulation (ADAMTS13 and WVF) and miRNAs, in Diabetic kidney disease hemodialysis patients.

Diabetes mellitus (DM) is one of the most common chronic diseases in nearly all countries. Diabetic kidney disease (DKD) traditionally has been referred to as diabetic nephropathy and is one of the microvascular complications of diabetes. Diabetic kidney disease (DKD) occurs in 25%-40% of patients with diabetes .

Some studies have shown that the high risk of cardiovascular disease in diabetic patients with nephropathy is associated with increased plasma levels of von Willebrand factor (VWF) and decreased ADAMTS13 levels. VWF is a glycoprotein that plays an important role in platelet thrombus formation, whereas ADAMTS13 is a proteolytic enzyme that is responsible for degradation of large multimers of VWF released in the plasma by endothelial cells and platelets. Patients with both chronic kidney disease and diabetes have been shown to have higher plasma levels of VWF and decreased ADAMTS13 activity compared to healthy controls.

Increased plasma levels of VWF, which reflects damage to endothelial cells and a hypercoagulability state, have been reported in atherosclerosis and diabetes. Thus, VWF and ADAMTS13 seem to be important players in the interface between diabetic nephropathy, hypercoagulability and atherosclerotic cardiovascular disease. Vitamin D deficiency is a risk factor for DM and hypertension. The investigators previous studies showed that adding calcitriol (activated vitamin D) to endothelial and vascular smooth muscle cells significantly down-regulated the inflammatory response of gene and protein expression involved in the nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB) signal transduction pathway. Micro RNA (miRNA) are short noncoding RNAs, 22-25 nucleotides long. As an endogenous production transcript, miRNAs can bind to the 3 untranslated regions (3 UTR) of its target messenger RNA (mRNA) in an imperfect, complementary manner, leading to post-transcriptional gene silencing. As a result, miRNAs can inhibit gene expression via mRNA degradation, translation inhibition, or transcriptional inhibition.The critical role of miRNAs has been established in several cellular and biologic processes, such as proliferation, differentiation, and development, and in the regulation of genes related to immune responses, cancer, and insulin secretion. MiRNA are involved in various biological processes and become novel biomarkers, modulators and therapeutic targets for diseases such as cancer, atherosclerosis, and DM.

Significance: The high prevalence of cardiovascular morbidity and mortality in patients with DM on chronic hemodialysis remains a significant clinical problem and the finding of potential new biomarkers should be further investigated. This study aims to establish a link between ADAMTS13, VWF miRNA expression and vitamin D levels that can contribute to the development of new treatments for hemodialysis patients with diabetes.

Methods: Each hemodialysis patient with diabetes in the investigators institute will be asked to participate in the study. After explaining the research goals, patients that agree to participate will sign an informed consent. The investigators estimate that the study will include 70 patients. Each patient will be assessed by a physician and 4 vials of blood will be taken while the patient is connected to the dialysis machine. The blood will be sent to the laboratory to check: 1) chemistry; 2) 1-25 vitamin D and 25- vitamin D levels; 3) ADAMTS13 activity and VWF; and 4) miRNA extraction. The patients will be grouped according to vitamin D levels (deficient /sufficient), and ADAMTS13, VWF and miRNA expression will be compared between the groups.


Condition or disease
Hemodialysis Patients Diabetes

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 5 Years
Study Start Date : September 2014
Estimated Primary Completion Date : February 2015
Estimated Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis Vitamin D
Drug Information available for: Vitamin D

Group/Cohort
vitamin D levels deficient
Diabetic hemodialysis patients with vitamin D levels deficient
vitamin D levels sufficient
Diabetic hemodialysis patients with vitamin D levels sufficient



Primary Outcome Measures :
  1. ADAMTS13 levels in diabetic hemodialysis patients [ Time Frame: 1 day ]
    blood will be collected from diabetic hemodialysis patients that will arrived to the hospital for receive dialysis for analysis ADAMTS13 levels


Secondary Outcome Measures :
  1. VWF levels in diabetic hemodialysis patients [ Time Frame: 1 day ]
    blood will be collected from diabetic hemodialysis patients that will arrived to the hospital for receive dialysis for analysis VWF levels


Other Outcome Measures:
  1. miRNA expression in plasma from diabetic hemodialysis patients [ Time Frame: 1 day ]
    blood will be collected from diabetic hemodialysis patients that will arrived to the hospital for receive dialysis for extract miRNA


Biospecimen Retention:   Samples With DNA
miRNA will be extract from patient'w plasma


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hemodialysis patients with diabetes at Meir Medical Center
Criteria

Inclusion Criteria:

  • Clinical diagnosis of chronic kidney disease - hemodialysis patient with diabetes

Exclusion Criteria:

  • Hemodialysis patient - non diabetic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02245633


Contacts
Layout table for location contacts
Contact: Sydney bensitrit, MD +972-9-7472517 sydneybe@clalit.org.il

Locations
Layout table for location information
Israel
Nephrology dept. Meir Medical Center Recruiting
Kfar Saba, Israel, 44281
Contact: Sydney Bensitrit, MD       sydneybe@clalit.org.il   
Principal Investigator: Sydney Bensitrit, MD         
Sponsors and Collaborators
Meir Medical Center

Additional Information:

Layout table for additonal information
Responsible Party: Sydney Ben Shitrit, Dr., Meir Medical Center
ClinicalTrials.gov Identifier: NCT02245633     History of Changes
Other Study ID Numbers: 0081-14-MMC
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamins
Vitamin D
Ergocalciferols
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents